For patients with three or fewer tumor metastases, the median PFS were 13.2 months (95% CI, 9.1–17.4 months) and 7.4 months (95% CI, 5.7–9.1 months) (p = 0.545) (Figure 5) for the MWA plus EGFR-TKIs group and the EGFR-TKIs group, respectively, and the corresponding OS were 38.0 months (95% CI, 28.8–47.2 months) and 23.3 months (95% CI, 12.2–34.3 months), respectively (p = 0.212) (Figure 6). This evidence concerns the gene EGFR and neoplasm.